Khalil Amjad, Quaglia Alberto, Gélat Pierre, Saffari Nader, Rashidi Hassan, Davidson Brian
Liver Unit, Wellington Hospital, London NW8 9TA, UK.
Centre for Surgical Innovation, Organ Regeneration and Transplantation, University College London, London NW3 2PS, UK.
J Clin Med. 2023 Aug 27;12(17):5586. doi: 10.3390/jcm12175586.
Liver disease is increasing in incidence and is the third most common cause of premature death in the United Kingdom and fourth in the United States. Liver disease accounts for 2 million deaths globally each year. Three-quarters of patients with liver disease are diagnosed at a late stage, with liver transplantation as the only definitive treatment. Thomas E. Starzl performed the first human liver transplant 60 years ago. It has since become an established treatment for end-stage liver disease, both acute and chronic, including metabolic diseases and primary and, at present piloting, secondary liver cancer. Advances in surgical and anaesthetic techniques, refined indications and contra-indications to transplantation, improved donor selection, immunosuppression and prognostic scoring have allowed the outcomes of liver transplantation to improve year on year. However, there are many limitations to liver transplantation. This review describes the milestones that have occurred in the development of liver transplantation, the current limitations and the ongoing research aimed at overcoming these challenges.
肝病的发病率正在上升,在英国是过早死亡的第三大常见原因,在美国是第四大常见原因。肝病每年在全球导致200万人死亡。四分之三的肝病患者在晚期才被诊断出来,肝移植是唯一的确定性治疗方法。60年前,托马斯·E·斯塔兹尔进行了首例人体肝移植。自那以后,肝移植已成为治疗终末期肝病(包括急性和慢性肝病,以及代谢性疾病、原发性肝癌,目前正在试行的继发性肝癌)的既定疗法。外科手术和麻醉技术的进步、对移植适应症和禁忌症的细化、供体选择的改善、免疫抑制以及预后评分等,使得肝移植的效果逐年提高。然而,肝移植存在许多局限性。本综述描述了肝移植发展过程中的里程碑、当前的局限性以及旨在克服这些挑战的正在进行的研究。